By Alicia Gailliez, Business Development Manager, One Nucleus
It is well accepted that if a business wishes to attract partners or clients, advertisements in trade and technical publications in their field can be extremely effective. Aligning with content of interest and relevance to the target audience can see increased sales, product enquiries, a higher profile, trade partnerships and even potential investors. The barrier, as is often the case, is the available marketing budget, how it can be best deployed and how to make that buying decision.
Useful measurement tools including circulation…
By Alicia Gailliez, Business Development Manager, One Nucleus
CRISPR is short for “clustered regularly interspaced short palindromic repeats”. An article from The Jackson Laboratory on ‘What is CRISPR’ describes how the term makes reference to the repetitive pattern of DNA and “spacer” sequences in bacteria. It was discovered that bacteria transcribe these DNA elements to RNA upon viral infection. The RNA guides a nuclease (a protein that cleaves DNA) to the viral DNA to cut it, providing protection against the virus. The nucleases are named “Cas,” for “CRISPR-associated.”
This concept…
By Tony Jones, CEO, One Nucleus
Building on the development of the Bridge to Boston activities commenced at the One Nucleus Breakfast at BIO 2023 hosted by McDermott Will & Emery, followed by the Boston Bootcamp in April this year and the Breakfast at BIO 2024 with Mintz; One Nucleus continues to explore the opportunities to support the international investment, collaboration, and outsourcing deal flow needs of our members. Of course, the starting point for such support is the day-to-day support we offer our members locally in order to facilitate them being the best versions of themselves…
Research conducted by Pioneer Group sheds light on the current investment trends shaping the life sciences landscape, offering insights into where capital is being allocated and what it means for the sector.
The fall in venture capital investment levels over recent years has caused some concern in the real estate sector.
However, it’s important to note that 2021 witnessed a whirlwind of venture capital activity, particularly in the first and second quarters. These periods were marked by a handful of colossal investments, including landmark figures pumped into entities like CMR Surgical,…
Blog written by Elisabeth Goodman of RiverRhee Consulting...
Introduction by Monalisa Breazu, Learning & Development Administrator, One Nucleus:Following on from our Building Life Science Adventures (BLSA) conference series, we are delighted to be able to continue those conversations with a new BLSA Special Interest Group (BLSA SIG). What this means is that this will now be a series of shorter seminars/workshops to deliver valuable advice and fill knowledge gaps on key topics to best support our members in retaining and developing teams.
We’re thrilled to share that our first…
Guest blog by Mitigo
Deepfake technology, which uses Artificial Intelligence (AI) to create highly realistic but fake images, audio, and videos, is rapidly emerging as a significant threat in the cyber security landscape. As cyber criminals adopt this technology to exploit vulnerabilities, businesses must understand its implications and strengthen their defences.
What are Deepfakes?Deepfakes involve the use of AI algorithms to create convincing forgeries of individuals' likenesses. This technology can fabricate realistic images, videos, and audio recordings, making it increasingly difficult…
At this year’s ON Helix event ‘New Horizons for BIO Innovation’, a key note session expertly moderated by Precision Life’s Rowan Gardner, covered the ins and outs, or ones and zeros, of Tech-Bio. But first, have you protected all your valuable digital data from exfiltration? Is your cybersecurity up to snuff? A hostile attack leading to extortion and worse, can be just one click anyway, as data security expert Naveen Kaushik from ZenZero demonstrated. In May, United Health confirmed the company paid hackers a $22m ransom, which led to questioning of the CEO by US Senators.
Assuming you have…
Tony Jones, CEO and Richard Dickinson, Chief Technical Specialist, One Nucleus
The path from ideation to patient benefit in bio-innovation can be a long and winding route involving a myriad of people, institutions and companies. It's not a journey for the faint-hearted as one might suggest when it’s possible to take so many wrong turns or simply be outdone by nature, yet we see progress year on year against many disorders, so it’s as well that the life sciences industry is packed with brave-hearts rather than faint-hearts. The curiosity, passion, optimism and resilience among bio-…
Guest blog by Aon...
Too many investments in life science companies are made without the appropriate human capital due diligence which can lead to problems post-deal in areas like poor talent retention and excessive salary costs. Aon’s Keaton Hoffman – Partner, Executive Compensation, Talent Solutions and Matthew Robinson – Life Science Industry Leader, explore why getting the human capital due diligence right is vital and where venture capital firms and the wider private equity market should be focusing.
The life sciences industry is primed for investment. Figures from EY reveal total M&…
By Tony Jones, CEO, One Nucleus
There is a plethora of research and commentary available in leading publications such as the Harvard Business Review, supporting the fact that curiosity can be an essential and extremely beneficial characteristic to encourage in the workplace. Team leaders often associate this trait in their employees with high performance, bringing innovative solutions to complex challenges. It is clearly not a one-way street either, with curious leaders breeding a sense of security in their teams to be innovative and giving confidence to be challenging. Many will also see…